What Will Happen to Achieve Life Sciences, Inc. (ACHV) Next? The Stock Just Reaches All-Time Low

June 19, 2018 - By Winifred Garcia

The stock of Achieve Life Sciences, Inc. (NASDAQ:ACHV) reached all time low today, Jun, 20 and still has $3.05 target or 9.00 % below today’s $3.35 share price. This indicates more downside for the $6.70 million company. This technical setup was reported by Barchart.com. If the $3.05 PT is reached, the company will be worth $603,360 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 4.83% or $0.17 during the last trading session, reaching $3.35. About 148,670 shares traded or 117.50% up from the average. Achieve Life Sciences, Inc. (NASDAQ:ACHV) has declined 74.49% since June 20, 2017 and is downtrending. It has underperformed by 87.06% the S&P500.

More notable recent Achieve Life Sciences, Inc. (NASDAQ:ACHV) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018, also Benzinga.com with their article: “30 Stocks Moving In Friday’s Mid-Day Session” published on June 15, 2018, Nasdaq.com published: “Mid-Morning Market Update: Markets Open Lower; Adobe Beats Q2 Expectations” on June 15, 2018. More interesting news about Achieve Life Sciences, Inc. (NASDAQ:ACHV) were released by: Seekingalpha.com and their article: “Achieve Life Sciences continues selloff, down 13% premarket” published on June 15, 2018 as well as Benzinga.com‘s news article titled: “40 Biggest Movers From Yesterday” with publication date: June 15, 2018.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company has market cap of $6.70 million. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: